WO2013166399A1 - Ophthalmic compositions with improved dessication protection and retention - Google Patents

Ophthalmic compositions with improved dessication protection and retention Download PDF

Info

Publication number
WO2013166399A1
WO2013166399A1 PCT/US2013/039487 US2013039487W WO2013166399A1 WO 2013166399 A1 WO2013166399 A1 WO 2013166399A1 US 2013039487 W US2013039487 W US 2013039487W WO 2013166399 A1 WO2013166399 A1 WO 2013166399A1
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
composition according
present
hyaluronic acid
guar
Prior art date
Application number
PCT/US2013/039487
Other languages
English (en)
French (fr)
Inventor
James W. Davis
Howard Allen Ketelson
Elaine E. CAMPBELL
David L. Meadows
Rekha Rangarajan
Original Assignee
Alcon Research, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UAA201412705A priority Critical patent/UA113434C2/uk
Priority to ES13723623T priority patent/ES2761373T3/es
Priority to AU2013256144A priority patent/AU2013256144B2/en
Priority to MX2014013444A priority patent/MX362266B/es
Priority to DK13723623.8T priority patent/DK2844226T3/da
Priority to RU2014148758A priority patent/RU2659207C2/ru
Priority to KR1020147032805A priority patent/KR102076033B1/ko
Priority to PL13723623T priority patent/PL2844226T3/pl
Priority to CN201380031008.8A priority patent/CN104379131A/zh
Priority to CA2872622A priority patent/CA2872622C/en
Application filed by Alcon Research, Ltd. filed Critical Alcon Research, Ltd.
Priority to IN2248MUN2014 priority patent/IN2014MN02248A/en
Priority to BR112014027582-3A priority patent/BR112014027582B1/pt
Priority to PH1/2014/502571A priority patent/PH12014502571B1/en
Priority to EP13723623.8A priority patent/EP2844226B1/en
Publication of WO2013166399A1 publication Critical patent/WO2013166399A1/en
Priority to ZA2014/08490A priority patent/ZA201408490B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Definitions

  • the present invention relates to artificial tear compositions and compositions for ophthalmic drug delivery, and more specifically to compositions comprising a galactomannan such as guar, hyaluronic acid, and a cis-diol.
  • a galactomannan such as guar, hyaluronic acid, and a cis-diol.
  • Ophthalmic compositions for topical application comprise compounds that lubricate and protect the ocular surface.
  • artificial tear compositions can prevent symptoms such as pain and discomfort and can prevent bioadhesion and tissue damage induced by friction.
  • a large number of potential compounds are available that are useful as lubricants and ocular surface protectants.
  • certain marketed artificial tear products contain natural polymers such as galactomannans.
  • Other lubricants and ocular surface protectants include, for example, carboxymethylcellulose, glucomannan, glycerol, and hydroxypropylmethylcellulose.
  • the present invention relates to ophthalmic dry eye compositions comprising guar and hyaluronic acid.
  • a cis ⁇ diol s such as sorbitol or propylene glycol, is also present in the compositions, in certain embodiments, a borate compound is also present in the compositions.
  • the compositions of the invention provide improved desiccation protection and retention characteristics.
  • the compositions of the present invention are also useful as drug delivery vehicles for ophthalmic therapeutics.
  • the present inventors have discovered that the combination of guar and hyaluronic acid demonstrates a synergistic effect relative to desiccation protection and ocular surface retention when compared to compositions containing either polymer alone. Furthermore, the compositions of the present invention demonstrated improved stability when subjected to elevated temperatures such as those encountered during sterilization processes such as autociavmg.
  • FIGURE 1 is a bar chart comparing desiccation performance of a composition comprising both hydroxypropyl guar and hyaluronic acid to compositions comprising either hydroxypropyl guar or hyaluronic acid;
  • FIGURE 2 is a is a bar chart comparing retention performance of a composition comprising hydroxypropyl guar and hyaluronic acid to compositions comprising hydroxypropyl guar and hyaluronic acid alone;
  • FIGURE 3 is a bar chart comparing retention of fluorescently-tagged polymer compositions.
  • FIGURE 4 is a bar chart comparing retention of a hydroxypropyl guar/hyaluronic acid composition with a hyaluronic acid/carboxvmethylcellulose composition.
  • compositions of the present invention comprise a galactoraannan such as guar, hyaluronic acid, and a cis-diol.
  • a galactoraannan such as guar, hyaluronic acid, and a cis-diol.
  • the types of galactomannans that may be used in the present invention are typically derived from guar gum, locust bean gum and tara gum.
  • the term "galactomannan” refers to polysaccharides derived from the above natural gums or similar natural or synthetic gums containing mannose or galactose moieties, or both groups, as the main structural components.
  • Preferred galactomannans of the present invention are made up of linear chains of (l-4)-p-D- mannopyranosyl units with a-D-galactopyranosyl units attached by (1 -6) linkages.
  • the ratio of D-galactose to D-mannose varies, but generally will be from about 1 :2 to 1 :4, Galactomannans having a D-gaiactose:D- mannose ratio of about 1 :2 are most preferred.
  • other chemically modified variations of the polysaccharides are also included in the "galactomannan" definition. For example, hydroxyethyl, hydroxypropy!
  • Non-ionic variations to the galactomannans such as those containing alkoxy and alkyl (C1-C6) groups are particularly preferred when a soft gel is desired (e.g., hydroxylpropyl substitutions). Substitutions in the non-cis hydroxy! positions are most preferred.
  • An example of non-ionic substitution of a galactomannan of the present invention is hydroxypropyl guar, with a molar substitution of about 0.4.
  • Anionic substitutions may also be made to the galactomannans. Anionic substitution is particularly preferred when strongly responsive gels are desired.
  • a galactomannan is typically present in a composition of the present invention at a concentration of about 0.025 to about 0.8 w/v%, preferably at about 0.1 w/v% to about 0.2 w/v%, and more preferably at about 0.17 to about 0.18 w/v%.
  • hydroxypropyl guar is present at a concentration of about 0.175 w/v%.
  • Preferred galactomannans of the present invention are guar and hydroxypropyl guar. Hydroxypropyl guar is particularly preferred.
  • Glycosaminoglycans such as hyaluronic acid are negatively charged molecules.
  • Hyaluronic acid is an unsulphated glycosaminoglycan composed of repeating disaccharide units of N-acetylglucosamine (GlcNAc) and glucuronic acid (GlcUA) linked together by alternating beta- 1,4 and beta- 1,3 glycosidic bonds.
  • Hyaluronic acid is also known as hyaluronan, hyaluronate, or HA.
  • hyaluronic acid also includes salt fonns of hyaluronic acid such as sodium hyaluronate
  • Compositions of the present invention comprise from about 0.05 to about 0.5 w/v% hyaluronic acid.
  • hyaluronic acid is present at a concentration of about 0.1 to about 0.2 w/v%, and more preferably at a concentration of about 0.13 to 0.17 w/v%.
  • sodium hyaluronate is present at a concentration of about 0.15 w/v%.
  • a preferred hyaluronic acid is sodium hyaluronate.
  • the molecular weight of the hyaluronic acid used in compositions of the present invention may vary, but is typically 0.5 to 2.0M Daltons. In one embodiment, the hyaluronic acid has a molecular weight of 900,000 to 1M Daltons. in another embodiment, the hyaluronic acid has a molecular weight of 1.9 to 2.0 M Daltons.
  • the cis-diol compounds that may be used with embodiments of the present invention include, but are not limited to, hydrophilic carbohydrates such as sorbitol or rnannitol that comprise cis-diol groups (hydroxyl groups attached to adjacent carbon atoms).
  • hydrophilic carbohydrates such as sorbitol or rnannitol that comprise cis-diol groups (hydroxyl groups attached to adjacent carbon atoms).
  • Preferred cis-diol compounds of the present invention include polyethylene glycols, polypropylene glycols, and polyethyleneoxide-polybutyieneoxide block copolymers. Particularly preferred cis-diol compounds are sorbitol and rnannitol.
  • the cis-diol compounds are present at concentrations of about 0.5 to 5.0 w/v% in the compositions of the present invention, and are preferably present at a concentration of about 1.0 to 2.0 w/v%. In one embodiment, sorbitol is present at a concentration of about 1.4%. Generally, the molecular weight of such cis-diol compounds is between 400 g/mo! to 5 million g/mol.
  • borate When present in a composition of the present invention, borate is typically at a concentration of about 0.1 to about 1.8 w/v%. in a preferred embodiment, borate is present at a concentration of 0.3 to 0.4 w/v%. in one embodiment of the present invention, boric acid is present at a concentration of about 0.35 w/v%.
  • borate refers to all pharmaceutically suitable forms of borates, including but not limited to boric acid, and alkali metal borates such as sodium borate and potassium borate. Boric acid is the preferred borate used with embodiments of the present invention.
  • the compositions of the present invention may optionally comprise one or more additional excipients and/or one or more additional active ingredients.
  • Excipients commonly used in pharmaceutical compositions include, but are not limited to, demulcents, tonicity agents, preservatives, chelating agents, buffering agents, and surfactants.
  • Other excipients comprise solubilizing agents, stabilizing agents, comfort-enhancing agents, polymers, emollients, pH-adjusting agents and/or lubricants.
  • compositions of the present invention including water, mixtures of water and water-miscible solvents, such as Cl- C7-aikanols, vegetable oils or mineral oils comprising from 0.5 to 5% non-toxic water-soluble polymers, natural products, such as alginates, pectins, tragacanth, karaya gum, xanthan gum, carrageenin, agar and acacia, starch derivatives, such as starch acetate and hydroxypropyl starch, and also other synthetic products such as polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl methyl ether, polyethylene oxide, preferably cross-linked polyacrylic acid and mixtures of those products.
  • water-miscible solvents such as Cl- C7-aikanols
  • vegetable oils or mineral oils comprising from 0.5 to 5% non-toxic water-soluble polymers
  • natural products such as alginates, pectins, tragacanth, karaya gum,
  • Demulcents used with embodiments of the present invention include, but are not limited to, glycerin, polyvinyl pyrroiidone, polyethylene oxide, polyethylene glycol, propylene glycol and polyacrylic acid. Particularly preferred demulcents are propylene glycol and polyethylene glycol 400.
  • Suitable tonicity-adjusting agents include, but are not limited to, mannitol, sodium chloride, glycerin, and the like.
  • Suitable buffering agents include, but are not limited to, phosphates, acetates and the like, and amino alcohols such as 2-amino-2- methyl- 1-propanol (AMP).
  • Suitable surfactants include, but are not limited to, ionic and nonionic surfactants, though nonionic surfactants are preferred, RLM 100, POE 20 cetylsteary! ethers such as Procol ® CS20 and poloxamers such as Pluronic ® F68.
  • compositions set forth herein may comprise one or more preservatives.
  • preservatives include p-hydroxybenzoic acid ester, sodium perborate, sodium chlorite, alcohols such as chlorobutanol, benzyl alcohol or phenyl ethanol, guanidine derivatives such as polyhexamethylene biguanide, sodium perborate, polyquaternium-1, or sorbic acid.
  • the composition may be self-preserved so that no preservation agent is required.
  • compositions of the present invention are ophthalmicaily suitable for application to a subject's eyes.
  • aqueous typically denotes an aqueous composition wherein the excipient is >50%, more preferably >75% and in particular >90% by weight water.
  • These drops may be delivered from a single dose ampoule which may preferably be sterile and thus render bacteriostatic components of the composition unnecessary.
  • the drops may be delivered from a multi- dose bottle which may preferably comprise a device which extracts any preservative from the composition as it is delivered, such devices being known in the art.
  • the compositions of the present invention are preferably isotonic, or slightly hypotonic in order to combat any hypertonicity of tears caused by evaporation and/or disease.
  • compositions of the present invention generally have an osmolality in the range of 220-320 mOsm/kg, and preferably have an osmolality in the range of 235-300 mOsm/kg,
  • the ophthalmic compositions will generally be formulated as sterile aqueous solutions.
  • compositions of the present invention can also be used to administer pharmaceutically active compounds for the treatment of, for example, ophthalmic diseases such as glaucoma, macular degeneration, and ocular infections.
  • ophthalmic diseases such as glaucoma, macular degeneration, and ocular infections.
  • Such compounds include, but are not limited to, glaucoma therapeutics, pain relievers, anti- inflammatory and anti-allergy medications, and anti-microbials.
  • pharmaceutically active compounds include betaxolol, timolol, pilocarpine, carbonic anhydrase inhibitors and prostglandins; dopaminergic antagonists; post-surgical antihypertensive agents, such as para-amino clonidine (apraclonidine); anti-infectives such as ciprofloxacin, moxifloxacin, and tobramycin; non-steroidal and steroidal anti-inflammatories, such as naproxen, diclofenac, nepafenac, suprofen, ketorolac, tetrahydrocortisol and dexamethasone; dry eye therapeutics such as PDE4 inhibitors; and and-aliergy medications such as H1 /M4 inhibitors, H4 inhibitors, and olopatadine.
  • post-surgical antihypertensive agents such as para-amino clonidine (apraclonidine)
  • anti-infectives such as cip
  • compositions of the present invention can vary. A person of ordinary skill in the art would understand that the concentrations can vary depending on the addition, substitution, and/or subtraction of ingredients in a given composition.
  • Preferred compositions are prepared using a buffering system that maintains the composition at a pH of about 6.5 to a pH of about 8.0.
  • Topical compositions are preferred which have a physiological pH matching the tissue to which the composition will be applied or dispensed.
  • a composition of the present invention is administered once a day. However, the compositions may also be formulated for administration at any frequency of administration, including once a week, once every
  • Such dosing frequency is also maintained for a varying duration of time depending on the therapeutic regimen.
  • the duration of a particular therapeutic regimen may vary from one-time dosing to a regimen that extends for months or years.
  • One of ordinary skill in the art would be familiar with determining a therapeutic regimen for a specific indication.
  • Guar and hyaluronate compositions of the present invention were autoclaved under standard conditions. As shown below in Table 1, the composition comprising sorbitol has a stabilized molecular weight when compared with the composition that did not contain sorbitol.
  • compositions of the present invention to protect human epithelial cells from desiccating stress was evaluated as follows.
  • Human transformed corneal epithelial cells were plated at 0.09 x 10 6 cells roL onto collagen-coated 48- well plates (BD Biosciences #35-4505) and grown to confluence in EpiLife media (Invitrogen #MEPI500CA) supplemented with Human Corneal Growth Supplement (HCGS invitrogen #80095) for 48 hours. Cells were treated with test solutions for 30 minutes at 37°C then rinsed IX (250 ⁇ ) with supplement free media. All solutions were gently removed and the cells were subjected to desiccation at 45% humidity, 37°C for 30 minutes in a desiccation chamber (Caron Environmental Chamber 6010 Series).
  • HPG hydroxypropyl guar composition
  • HA hyaluronic acid composition
  • HPG/ ⁇ hydroxypropyl guar and hyaluronic acid
  • the DPS composition demonstrated significantly greater desiccation protection than either the HPG solution or the HA solution.
  • the HPG/HA solution also demonstrated greater retention to the epithelial surface than either the HPG solution or the HA solution.
  • a synergistic effect was noted relative to both desiccation protection and retention behavior of the HPG/HA solution.
  • the mean retention time of a composition of the present invention was compared to its components alone. Briefly, a fluorescein labeled dextran tracer of approximately 70 kD (Molecular Probes, Eugene, Oregon) was added to each test formulation at a concentration of 0.1 w/v%. A scanning fluorophotometer (Ocumetrics, Mountain View, California) was used to monitor signal decay corresponding to elimination of the formulations. As shown in FIGURE 3 and TABLE 4 below, individual fluorescent tagging of the polymer components of the HPG HA solution demonstrates an increase in the amount of polymer bound to the epithelial surface when the polymers hydroxypropyl guar and hyaluronic acid are combined. FIGURE 4 and TABLE 5 demonstrate that this improved retention effect was not noted in a dual polymer formulation comprising hyaluronic acid and carboxyrnethylceilulose (HA/CMC).
  • HA/CMC carboxyrnethylceilulose
  • HPG/HA Hydroxy Propyl Guar/Hyaluronic Acid
  • HPG HydroxyPropyl Guar
  • HPG/HA HydroxyPropyl G ar/Hyaluronic Acid
  • s ⁇ 0.05 Statistical significance based on one-way ANOVA relative to HA alone and HA/CMC compositions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/US2013/039487 2012-05-04 2013-05-03 Ophthalmic compositions with improved dessication protection and retention WO2013166399A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
UAA201412705A UA113434C2 (uk) 2012-05-04 2013-03-05 Офтальмологічна композиція з поліпшеним захистом від зневоднювання й утриманням
PL13723623T PL2844226T3 (pl) 2012-05-04 2013-05-03 Kompozycje okulistyczne o ulepszonej ochronie przed wysychaniem i zatrzymywaniu
MX2014013444A MX362266B (es) 2012-05-04 2013-05-03 Composiciones oftalmicas con retención y proteccion de desecación mejoradas.
DK13723623.8T DK2844226T3 (da) 2012-05-04 2013-05-03 Oftalmiske sammensætninger med forbedret udtørringsbeskyttelse og retention
RU2014148758A RU2659207C2 (ru) 2012-05-04 2013-05-03 Офтальмологические композиции с улучшенной защитой от обезвоживания и удерживанием
KR1020147032805A KR102076033B1 (ko) 2012-05-04 2013-05-03 건조 보호 및 체류가 개선된 안과 조성물
CN201380031008.8A CN104379131A (zh) 2012-05-04 2013-05-03 具有改善的干燥保护和保留的眼用组合物
ES13723623T ES2761373T3 (es) 2012-05-04 2013-05-03 Composiciones oftálmicas con protección contra la desecación y retención mejoradas
CA2872622A CA2872622C (en) 2012-05-04 2013-05-03 Ophthalmic compositions with improved dessication protection and retention
AU2013256144A AU2013256144B2 (en) 2012-05-04 2013-05-03 Ophthalmic compositions with improved dessication protection and retention
IN2248MUN2014 IN2014MN02248A (enrdf_load_stackoverflow) 2012-05-04 2013-05-03
BR112014027582-3A BR112014027582B1 (pt) 2012-05-04 2013-05-03 Composições oftalmicas com proteção e retenção de dessecação aperfeiçoada
PH1/2014/502571A PH12014502571B1 (en) 2012-05-04 2013-05-03 Ophthalmic compositions with improved dessication protection and retention
EP13723623.8A EP2844226B1 (en) 2012-05-04 2013-05-03 Ophthalmic compositions with improved dessication protection and retention
ZA2014/08490A ZA201408490B (en) 2012-05-04 2014-11-19 Ophthalmic compositions with improved dessication protection and retention

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642901P 2012-05-04 2012-05-04
US61/642,901 2012-05-04

Publications (1)

Publication Number Publication Date
WO2013166399A1 true WO2013166399A1 (en) 2013-11-07

Family

ID=48464107

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/039487 WO2013166399A1 (en) 2012-05-04 2013-05-03 Ophthalmic compositions with improved dessication protection and retention

Country Status (19)

Country Link
US (6) US20130296264A1 (enrdf_load_stackoverflow)
EP (1) EP2844226B1 (enrdf_load_stackoverflow)
KR (1) KR102076033B1 (enrdf_load_stackoverflow)
CN (2) CN109157539A (enrdf_load_stackoverflow)
AR (1) AR090930A1 (enrdf_load_stackoverflow)
AU (1) AU2013256144B2 (enrdf_load_stackoverflow)
BR (1) BR112014027582B1 (enrdf_load_stackoverflow)
CA (1) CA2872622C (enrdf_load_stackoverflow)
DK (1) DK2844226T3 (enrdf_load_stackoverflow)
ES (1) ES2761373T3 (enrdf_load_stackoverflow)
IN (1) IN2014MN02248A (enrdf_load_stackoverflow)
MX (1) MX362266B (enrdf_load_stackoverflow)
PH (1) PH12014502571B1 (enrdf_load_stackoverflow)
PL (1) PL2844226T3 (enrdf_load_stackoverflow)
PT (1) PT2844226T (enrdf_load_stackoverflow)
RU (1) RU2659207C2 (enrdf_load_stackoverflow)
UA (1) UA113434C2 (enrdf_load_stackoverflow)
WO (1) WO2013166399A1 (enrdf_load_stackoverflow)
ZA (1) ZA201408490B (enrdf_load_stackoverflow)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019162882A1 (en) * 2018-02-21 2019-08-29 Novartis Ag Lipid- based ophthalmic emulsion
US10632202B2 (en) 2016-03-04 2020-04-28 Johnson & Johnson Consumer Inc. Preservative containing compositions
RU2793333C2 (ru) * 2018-02-21 2023-03-31 Алькон Инк. Офтальмологическая эмульсия на основе липидов
NL2032726B1 (en) * 2021-11-23 2023-06-15 Eye Hospital Wenzhou Medical Univ Diquafosol sustained-release gel, preparation method and use thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6357228B2 (ja) 2013-07-10 2018-07-11 マトリックス バイオロジー インスティテュート 高い弾性を有するヒアルロナンの組成物およびその使用
US10245324B2 (en) * 2014-10-31 2019-04-02 Johnson & Johnson Consumer Inc. Ophthalmic composition
CN105311042B (zh) * 2015-09-07 2019-04-12 广州国宇医药科技有限公司 一种糖醇组合物在制备治疗干眼症的药物中的应用
PL3842047T3 (pl) 2015-09-24 2024-10-28 Matrix Biology Institute Kompozycje hialuronanu o wysokiej elastyczności i sposoby ich zastosowania
TWI826685B (zh) * 2019-05-02 2023-12-21 瑞士商愛爾康公司 可溶解聚合物眼睛插入物及其使用方法
TWI757773B (zh) 2019-06-28 2022-03-11 瑞士商愛爾康公司 眼用組成物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09227385A (ja) * 1996-02-29 1997-09-02 Ofutekusu:Kk 眼手術用補助剤
US6403609B1 (en) 1997-07-29 2002-06-11 Alcon Manufacturing, Ltd. Ophthalmic compositions containing galactomannan polymers and borate
US20070128156A1 (en) * 2003-06-13 2007-06-07 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
US20090270345A1 (en) * 2008-04-26 2009-10-29 Alcon Research, Ltd. Polymeric artificial tear system
US20100087550A1 (en) * 2008-10-06 2010-04-08 Zora Marlowe Formulations with a Tertiary Amine Oxide
US20110275593A1 (en) * 2010-05-05 2011-11-10 Alcon Research, Ltd. Stabilized ophthalmic galactomannan formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2116227E (pt) * 2003-06-13 2013-06-28 Novartis Ag Composições oftálmicas que contêm uma combinação sinérgica de dois polímeros
EP2109442B1 (en) * 2007-02-09 2014-03-26 Novartis AG Ophthalmic compositions containing a synergistic combination of three polymers
US20090036554A1 (en) * 2007-08-01 2009-02-05 Burke Susan E Ophthalmic compositions comprising a terpene compound
US9096819B2 (en) * 2008-01-31 2015-08-04 Bausch & Lomb Incorporated Ophthalmic compositions with an amphoteric surfactant and an anionic biopolymer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09227385A (ja) * 1996-02-29 1997-09-02 Ofutekusu:Kk 眼手術用補助剤
US6403609B1 (en) 1997-07-29 2002-06-11 Alcon Manufacturing, Ltd. Ophthalmic compositions containing galactomannan polymers and borate
US20070128156A1 (en) * 2003-06-13 2007-06-07 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
US20090270345A1 (en) * 2008-04-26 2009-10-29 Alcon Research, Ltd. Polymeric artificial tear system
US20100087550A1 (en) * 2008-10-06 2010-04-08 Zora Marlowe Formulations with a Tertiary Amine Oxide
US20110275593A1 (en) * 2010-05-05 2011-11-10 Alcon Research, Ltd. Stabilized ophthalmic galactomannan formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199748, Derwent World Patents Index; AN 1997-516212, XP002714049 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10632202B2 (en) 2016-03-04 2020-04-28 Johnson & Johnson Consumer Inc. Preservative containing compositions
US11202832B2 (en) 2016-03-04 2021-12-21 Johnson & Johnson Consumer Inc. Preservative containing compositions
WO2019162882A1 (en) * 2018-02-21 2019-08-29 Novartis Ag Lipid- based ophthalmic emulsion
KR20200123408A (ko) * 2018-02-21 2020-10-29 알콘 인코포레이티드 지질-기재 안과용 에멀션
US10925892B2 (en) 2018-02-21 2021-02-23 Alcon Inc. Lipid-based ophthalmic emulsion
JP2021513515A (ja) * 2018-02-21 2021-05-27 アルコン インコーポレイティド 脂質ベースの眼科用エマルジョン
RU2793333C2 (ru) * 2018-02-21 2023-03-31 Алькон Инк. Офтальмологическая эмульсия на основе липидов
AU2019224830B2 (en) * 2018-02-21 2024-05-30 Alcon Inc. Lipid- based ophthalmic emulsion
JP7512198B2 (ja) 2018-02-21 2024-07-08 アルコン インコーポレイティド 脂質ベースの眼科用エマルジョン
KR102691673B1 (ko) 2018-02-21 2024-08-06 알콘 인코포레이티드 지질-기재 안과용 에멀션
RU2798842C1 (ru) * 2019-06-28 2023-06-28 Алькон Инк. Офтальмологические композиции
NL2032726B1 (en) * 2021-11-23 2023-06-15 Eye Hospital Wenzhou Medical Univ Diquafosol sustained-release gel, preparation method and use thereof

Also Published As

Publication number Publication date
ZA201408490B (en) 2016-08-31
CA2872622A1 (en) 2013-11-07
US20220273699A1 (en) 2022-09-01
RU2014148758A (ru) 2016-06-27
EP2844226B1 (en) 2019-11-13
US20170136057A1 (en) 2017-05-18
US11376275B2 (en) 2022-07-05
PH12014502571A1 (en) 2015-01-21
KR20150003868A (ko) 2015-01-09
US11672820B2 (en) 2023-06-13
CN109157539A (zh) 2019-01-08
US10828320B2 (en) 2020-11-10
US20210060056A1 (en) 2021-03-04
EP2844226A1 (en) 2015-03-11
AR090930A1 (es) 2014-12-17
CN104379131A (zh) 2015-02-25
AU2013256144A1 (en) 2014-12-04
PL2844226T3 (pl) 2020-04-30
MX362266B (es) 2019-01-10
RU2659207C2 (ru) 2018-06-28
DK2844226T3 (da) 2020-01-02
CA2872622C (en) 2020-07-28
US20130296264A1 (en) 2013-11-07
UA113434C2 (uk) 2017-01-25
PT2844226T (pt) 2019-12-16
BR112014027582A2 (pt) 2017-06-27
ES2761373T3 (es) 2020-05-19
US20200138853A1 (en) 2020-05-07
AU2013256144B2 (en) 2018-01-18
MX2014013444A (es) 2015-05-11
BR112014027582A8 (pt) 2021-06-15
US20230285443A1 (en) 2023-09-14
BR112014027582B1 (pt) 2022-05-10
KR102076033B1 (ko) 2020-02-11
PH12014502571B1 (en) 2022-04-29
IN2014MN02248A (enrdf_load_stackoverflow) 2015-07-24

Similar Documents

Publication Publication Date Title
US20230285443A1 (en) Ophthalmic compositions with improved dessication protection and retention
AU2011248129B2 (en) Stabilized ophthalmic galactomannan formulations
CA2947274C (en) Ophthalmic compositions and methods for treating eyes
JP6180443B2 (ja) 安定性が強化された水性医薬組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13723623

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2872622

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/013444

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 20147032805

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013723623

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14260442

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: A201412705

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 2013256144

Country of ref document: AU

Date of ref document: 20130503

Kind code of ref document: A

Ref document number: 2014148758

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2015518400

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014027582

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014027582

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20141104